An improved composition for inducing bone growth is provided that is a combination of at least DBM and an oxygen carrier. Injection/implantation of a composition of DBM and an oxygen carrier (e.g. a perfluorocarbon) results in enhancement of bone formation compared to DBM alone.

The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In yet other embodiments, the present invention provides methods of treating a disease or condition comprising administration of an IgG composition provided herein.

The invention relates to hemoglobin derivative, particularly hemoglobin which is co-conjugated with both fatty acid-linked polyethylene glycol (FA-PEG) derivatives and alkoxy polyethylene glycol (alkoxy-PEG) derivatives, and a method for making such hemoglobin derivative. Various embodiments of the invention include crosslinked hemoglobin which is co-conjugated with both FA-PEG derivatives and alkoxy-PEG derivatives. Such hemoglobin derivative according to the invention exhibit non-toxicity and extended intravascular retention time.

A buffered body fluid expander solution, in which the buffer is a physiologically acceptable buffer that is not an inorganic phosphate buffer, comprises calcium ions and magnesium ions at a concentration ratio of 5:1 to 1:1. The solutions are useful for the manufacture of medicaments and blood volume expanders, for treating hypovolemia or for treating the loss of extracellular and interstitial fluid in subjects suffering with burns, for treating respiratory and/or metabolic acidosis in a subject, for perfusion of the abdominal cavity during peritoneal dialysis of a subject with acute renal failure or an acute toxicity condition, for preventing and/or ameliorating reperfusion injury, and for delivering a therapeutic, test and/or synergistic agent to a subject, including a biological agent, such as at least one stem cell, peptide or genomic derived protein.

A method for measuring, adjusting and maintaining the level of blood volume in a patient is described. A blood volume expander composition includes, in combination, a standard unmodified protein, colloid or crystalloid and a fluorescently-labeled protein, colloid or crystalloid of approximately the same molecular weight. The use of blood volume expanders to measure, adjust and maintain the level of blood volume in a patient also is described.

The exemplary arrangements relate to ammonium salts of partially fluorinated organic acids. The exemplary arrangements also relate to methods of synthesis of the ammonium salts of partially fluorinated organic acids. The exemplary arrangements also relate to methods of use of the ammonium salts of partially fluorinated organic acids to produce stabilizing emulsions of the oil-in-water and/or water-in-oil type. The exemplary arrangements also relate to methods of use and applications of the ammonium salts of partially fluorinated organic acids, for example use as stabilizing agents in blood substitute preparations.

The present invention relates to a method of stabilizing a dialysis solution that includes calcium ions and bicarbonate ions, wherein a phosphate and/or an organic phosphate ester is added to the dialysis solution at a distance of time from its preparation.

A method of treating a mammal, including a human, comprising administering a therapeutically effective amount of a poly-oxygenated aluminum hydroxide composition to the mammal to improve mitochondrial function and efficiency. The poly-oxygenated aluminum hydroxide composition causes increased production of adenosine triphosphate (ATP) in the mammal. The poly-oxygenated aluminum hydroxide composition comprises a clathrate containing bioavailable pure (100%) oxygen gas (O.sub.2) molecules that are freely released to the mammal depending on the oxygen demand, i.e., more O.sub.2 molecules released in hypoxic regions. The administration can be oral and the bioavailable O.sub.2 molecules are time released into the mammal. The O.sub.2 bioavailability of poly-oxygenated aluminum hydroxide composition can be slow if the mammal, organ or tissue is well perfused and oxygenated, but rapid if hypoxic.

In some embodiments provided herein is a method of preparing cargo-loaded platelets, comprising: treating platelets with a cargo and with a loading buffer comprising a salt, a base, a loading agent, and optionally ethanol, to form the cargo-loaded platelets.

The present invention is directed to a method of preparing dehydrated blood products, comprising the steps of: (a) providing a hydrated blood product; (b) spray-drying the hydrated blood product to produce a dehydrated blood product, as well as dehydrated blood products made by the method. The present invention is directed to a method of treating a patient suffering from a blood-related disorder, comprising the steps of: (a) rehydrating a therapeutic amount of the dehydrated blood products to produce a rehydrated therapeutic composition; and (b) administering the rehydrated therapeutic composition to the patient. The present invention is directed to a bandage or surgical aid comprising the dehydrated blood products described above.